Biolife Solutions' Chief Human Resources Officer Aebersold Sarah sells 714 shares at $25.61/share.
ByAinvest
Wednesday, Sep 17, 2025 5:48 pm ET1min read
BLFS--
The transactions saw Mathew Aby selling 630 shares at $26.83 per share, totaling $16,902. Foster sold 511 shares at the same price, totaling $13,710. Wichterman sold 1,032 shares at $26.83 per share, totaling $27,688. These sales reduced their respective shareholdings but did not significantly impact their overall ownership percentages [1].
On September 15, 2025, Chief Human Resources Officer Sarah Aebersold sold 714 shares at a price of $25.61 per share, totaling $18,215. This sale was also conducted under a pre-established Rule 10b5-1(c) trading plan [1].
These transactions provide insights into the executives' long-term commitment to the company and their confidence in Biolife Solutions' future prospects. However, they also highlight the potential for significant changes in the executive team's ownership structure.
Biolife Solutions Inc. (BLFS) has announced that Chief Human Resources Officer Sarah Aebersold has sold 714 shares at a price of $25.61 per share on September 15, 2025.
Biolife Solutions Inc. (BLFS) has experienced significant executive share sales recently, with key officers selling a notable portion of their holdings. On September 11, 2025, Chief Scientific Officer Mathew Aby sold 630 shares, Chief Quality and Operations Officer Karen Foster sold 511 shares, and Chief Financial Officer Troy Wichterman sold 1,032 shares, all under a pre-established Rule 10b5-1(c) trading plan [1].The transactions saw Mathew Aby selling 630 shares at $26.83 per share, totaling $16,902. Foster sold 511 shares at the same price, totaling $13,710. Wichterman sold 1,032 shares at $26.83 per share, totaling $27,688. These sales reduced their respective shareholdings but did not significantly impact their overall ownership percentages [1].
On September 15, 2025, Chief Human Resources Officer Sarah Aebersold sold 714 shares at a price of $25.61 per share, totaling $18,215. This sale was also conducted under a pre-established Rule 10b5-1(c) trading plan [1].
These transactions provide insights into the executives' long-term commitment to the company and their confidence in Biolife Solutions' future prospects. However, they also highlight the potential for significant changes in the executive team's ownership structure.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet